Whereas the anatomic MRI-based information can detect treatment-induced inhibition of tumor growth, our metabolic imaging can confirm that the drug has in fact been delivered to the tumor and that the activity of the mutant IDH enzyme has been inhibited in situ. Here, IDH1 is linked to neoplasm.